Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis.
The efficacy, tolerance and ease of administration of a nutraceutical, carprofen or meloxicam were evaluated in a prospective, double-blind study on 71 dogs with osteoarthritis. The client-owned dogs were randomly assigned to one of the three treatments or to a placebo control group. The influence of osteoarthritis on the dogs' gait was described by comparing the ground reaction forces of the arthritic dogs and 10 normal dogs. Before the treatments began, and 30 and 60 days later, measurements were made of haematological and biochemical variables and of the ground reaction forces of the arthritic limb, and subjective assessments were made by the owners and by the orthopaedic surgeons. Changes in the ground reaction forces were specific to the arthritic joint, and were significantly improved by carprofen and meloxicam but not by the nutraceutical; the values returned to normal only with meloxicam. The orthopaedic surgeons assessed that there had been an improvement with carprofen and meloxicam, but the owners considered that there had been an improvement only with meloxicam. The blood and faecal analyses did not reveal any changes. The treatments were well tolerated, except for a case of hepatopathy in a dog treated with carprofen.
Moreau
M
M
Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, 3200 Sicotte, PO Box 5000, St-Hyacinthe.
Dupuis
J
J
Bonneau
N H
NH
Desnoyers
M
M
D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D002227:Carbazoles / Q000008:administration & dosage / Q000627:therapeutic use; D002809:Chondroitin Sulfates / Q000008:administration & dosage / Q000627:therapeutic use; D002908:Chronic Disease; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004311:Double-Blind Method; D005684:Gait; D005944:Glucosamine / Q000008:administration & dosage / Q000627:therapeutic use; D007794:Lameness, Animal; D017895:Manganese Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D000077239:Meloxicam; D010003:Osteoarthritis / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D015207:Osteoarthritis, Hip / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary; D020370:Osteoarthritis, Knee / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary; D011446:Prospective Studies; D012720:Severity of Illness Index; D013264:Stifle; D013843:Thiazines / Q000008:administration & dosage / Q000627:therapeutic use; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002227:Carbazoles; D017895:Manganese Compounds; D013843:Thiazines; D013844:Thiazoles; D002809:Chondroitin Sulfates; C007005:carprofen; D005944:Glucosamine; D001205:Ascorbic Acid; D000077239:Meloxicam